Evidence map›Paper›PMID 28825178›Full record

SynthesisMedical oncology (Northwood, London, England)2017

Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature.

Stella Capriglione, Daniela Luvero, Francesco Plotti, Corrado Terranova, Roberto Montera, Giuseppe Scaletta, Teresa Schirò, Gianmarco Rossini, Pierluigi Benedetti Panici, Roberto Angioli

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. SERS Immunosensors for Cancer Markers Detection.Materials (Basel, Switzerland) · 2023
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Phenotypic and Functional Analyses of B7S1 in Ovarian Cancer.Frontiers in molecular biosciences · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stella CapriglioneDepartment of Obstetrics and Gynaecology, University of Rome "Campus Bio-Medico", Via Alvaro del Portillo, 200 - 00128, Rome, Italy. s.capriglione@unicampus.it.ORCID http://orcid.org/0000-0001-6962-520X
Daniela LuveroDepartment of Obstetrics and Gynaecology, University of Rome "Campus Bio-Medico", Via Alvaro del Portillo, 200 - 00128, Rome, Italy.
Francesco PlottiDepartment of Obstetrics and Gynaecology, University of Rome "Campus Bio-Medico", Via Alvaro del Portillo, 200 - 00128, Rome, Italy.
Corrado TerranovaDepartment of Obstetrics and Gynaecology, University of Rome "Campus Bio-Medico", Via Alvaro del Portillo, 200 - 00128, Rome, Italy.
Roberto MonteraDepartment of Obstetrics and Gynaecology, University of Rome "Campus Bio-Medico", Via Alvaro del Portillo, 200 - 00128, Rome, Italy.
Giuseppe ScalettaDepartment of Obstetrics and Gynaecology, University of Rome "Campus Bio-Medico", Via Alvaro del Portillo, 200 - 00128, Rome, Italy.
Teresa SchiròDepartment of Obstetrics and Gynaecology, University of Rome "Campus Bio-Medico", Via Alvaro del Portillo, 200 - 00128, Rome, Italy.
Gianmarco RossiniDepartment of Obstetrics and Gynaecology, University of Rome "Campus Bio-Medico", Via Alvaro del Portillo, 200 - 00128, Rome, Italy.
Pierluigi Benedetti PaniciDepartment of Gynecology Obstetrics and Urology, Policlinico Umberto I, ''Sapienza'' University of Rome, Rome, Italy.
Roberto AngioliDepartment of Obstetrics and Gynaecology, University of Rome "Campus Bio-Medico", Via Alvaro del Portillo, 200 - 00128, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the improvement in overall survival for ovarian cancer (OC) patients, a fraction of patients with advanced-stage disease fails to respond to primary therapy and relapses in 70% of cases. For this reason, new predictive and monitoring tools are needed to identify OC recurrence and new biomarkers were studied, among which human epididymis 4 (HE4), primarily expressed in the reproductive and respiratory tracts, is one of the most promising, reporting a good sensitivity and specificity in detecting OC, overcoming the traditional role of carbohydrate antigen 125 (CA-125). In this review, we aim to discuss the latest evidence reported in the literature about the use of HE4 to monitor ovarian cancer treatment and to detect OC recurrence. We searched MEDLINE (PubMed), EMBASE, Cochrane Central Register of Controlled Trials, IBECS, BIOSIS, Web of Science, SCOPUS, congress abstracts, and Grey literature (Google Scholar; British Library) from January 1952 to June 2017. The search identified seven papers in line with eligibility criteria for this systematic review; all of them demonstrated a good performance of HE4 in OC recurrence. The challenge to anticipate the diagnosis of OC recurrence and to translate this early diagnosis of relapse in a survival and quality of life improvement is still open, and as reported in this review, HE4 may play a key role in this scenario. More studies are needed to validate and reinforce the role of HE4 in ovarian cancer recurrence and in its early detection.

Indexed as

Biomarkers, TumorCarcinoma, Ovarian EpithelialEarly Detection of CancerFemaleHumansNeoplasm Recurrence, LocalNeoplasms, Glandular and EpithelialOvarian NeoplasmsProteinsWAP Four-Disulfide Core Domain Protein 2Biomarkers, TumorProteinsWAP Four-Disulfide Core Domain Protein 2WFDC2 protein, humanHE4Ovarian cancerOvarian cancer recurrence

Identifiers

PMID28825178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.